Back to the articles
Join Dr. Thomas Tompkins at Pharmabiotics
Dr. Thomas Tompkins, Research Director at the Rosell Institute for Microbiome and Probiotics, by Lallemand will present the “Impact of a psychobiotic composition on mood, behavior and the gut-brain axis: What have we learned from 15 years of clinical intervention?” at Pharmabiotics 2020 Paris, on March 10 at 15:40.
“I am honored to present to the global microbiome community that will be gathering for the Pharmabiotics event in Paris. My presentation will outline the path of discovery from our earliest clinical studies in mildly stressed individuals and how this quickly led to studies in major depressive disorder.” Declared Dr. Tompkins.
Lallemand Health Solutions is a pioneer in the brain-gut axis field and has been leading researches and developing new probiotic formulas since the last decade in that area, in particular with its combination of L. helveticus Rosell®-52 and B. longum Rosell®-175, the first to be recognized for its specific benefits in stressed healthy adults by health authorities in Canada (Health Canada) and in Brazil (ANVISA). It is now the most documented psychobiotic in the world with five clinical studies and nine preclinical studies to better understand eight mechanisms of action.
Come meet the on-site team to discuss further about the Brain-Gut axis or other probiotic supplements and novel formulas and their proven effects to improve human health.